A double-blind study of citalopram versus placebo in the treatment of compulsive sexual behaviors in gay and bisexual men

Journal of Clinical Psychiatry

Volumn 67, Issue 12, 2006, Pages 1968-1973

  Wainberg, Milton L ^a,e   Muench, Frederick ^b   Morgenstern, Jon ^b   Hollander, Eric ^b   Irwin, Thomas W ^b   Parsons, Jeffrey T ^c   Allen, Andrea ^b   O'Leary, Ann ^d  

^a Howard Hughes Medical Institute   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c CITY UNIVERSITY OF NEW YORK   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; CYPROHEPTADINE;

ADULT; ARTICLE; BISEXUAL MALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EJACULATION DISORDER; HUMAN; MAJOR CLINICAL STUDY; MALE; MASTURBATION; OBSESSIVE COMPULSIVE DISORDER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PUBLIC HEALTH; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK REDUCTION; SEXUAL BEHAVIOR; SEXUAL DEVIATION; SEXUAL DYSFUNCTION; SEXUAL SATISFACTION; TREATMENT DURATION; TREATMENT OUTCOME; UNSAFE SEX;

EID: 33845983638     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v67n1218     Document Type: Article

References (29)

1. Kafka MP. Sertraline pharmacotherapy for paraphilias and paraphilia-related disorders: an open trial. Ann Clin Psychiatry 1994;6:189-195
2. Kafka MP, Prentky R. Fluoxetine treatment of nonparaphilic sexual addictions and paraphilias in men. J Clin Psychiatry 1992;53:351-358
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994
4. Black DW. The epidemiology and phenomenology of compulsive sexual behavior. CNS Spectrums 2000;5:26-35
5. Kafka MP. Psychopharmacological treatments for nonparaphitic compulsive sexual behaviors. CNS Spectrums 2000;5:49-59
6. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report, 2004. Available at: http://www.cdc.gov/hiv/topics/surveillance/resources/ reports/2004report/rA/2004SurveillanceReport.pdf. Accessibility verified September 26, 2006
7. Kalichman SC, Greenberg J, Abel GG. HIV-seropositive men who engage in high-risk sexual behavior: psychological characteristics and implications for prevention. AIDS Care 1997;9:441-450
8. Greenberg DM, Bradford JM, Curry S, et al. A comparison of treatment of paraphilias with three serotonin reuptake inhibitors: a retrospective study. Bull Am Acad Psychiatry Law 1996;24:525-532
9. Rothschild AJ. Sexual side effects of antidepressants. J Clin Psychiatry 2000;61(suppl 11):28-36
10. Kessler RC, Andrews G, Mroczek D, et al. The World Health Organization Composite International Diagnostic Interview Short Form (CIDI-SF). Int J Methods Psychiatr Res 1998;7:171-185
11. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition (SCID-I/P, Version 2.0). New York, NY: Biometrics Research, New York State Psychiatric Institute; 1995
12. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:217-222
13. Wei LJ. An application of an URN model to the design of sequential controlled clinical trials. J Am Statist Assoc 1978;73:559-563
14. Harvey KV, Balon R. Clinical implications of antidepressant drug effects on sexual function. Ann Clin Psychiatry 1995;7:189-201
15. Goodman WK, Price LH, Rasmussen SA. The Yale-Brown Obsessive Compulsive Scale, 1: development, use, and reliability. Arch Gen Psychiatry 1989;46:1006-1011
16. Hollander E, De Caria CM, Finkell JN, et al. A randomized double-blind fluvoxamine/placebo crossover trial in pathologic gambling. Biol Psychiatry 2000;47:813-817
17. Phillips KA, Hollander E, Rasmussen SA, et al. A severity rating scale for body dysmorphic disorder: development, reliability, and validity of a modified version of the Yale-Brown Obsessive Compulsive Scale. Psychopharmacol Bull 1997;33:17-22
18. Modell JG, Glaser FB, Mountz JM, et al. Obsessive and compulsive characteristics of alcohol abuse and dependence: quantification by a newly developed questionnaire. Alcohol Clin Exp Res 1992;16:266-271
19. Coleman E, Miner M, Ohlerking F, et al. Compulsive Sexual Behavior Inventory: a preliminary study of reliability and validity. J Sex Marital Ther 2001;27:325-332
20. Weinhardt LS, Carey MP, Maisto SA, et al. Reliability of the Timeline Follow-Back sexual behavior interview. Ann Behav Med 1998;20:25-30
21. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
22. McGahuey CA, Gelenberg AJ, Laukes CA, et al. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther 2000;26:25-40
23. Hollander E, Tracy KA, Swann AC, et al. Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders. Neuropsychopharmacology 2003;28:1186-1197
24. Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Pers Soc Psychol 1986;51:1173-1182
25. Mitchell KJ, Finkelhor D, Wolak J. The Internet and family and acquaintance sexual abuse. Child Maltreat 2005;10:49-60
26. Kafka MP, Hennen J. Psychostimulant augmentation during treatment with selective serotonin reuptake inhibitors in men with paraphilias and paraphilia-related disorders: a case series. J Clin Psychiatry 2000;61:664-670
27. Goodman WK, McDougle CJ, Barr LC, et al. Biological approaches to treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 1993;54(6, suppl):16-26
28. Kaplan A, Hollander E. A review of pharmacologic treatments for obsessive-compulsive disorder. Psychiatr Serv 2003;54:1111-1118
29. Yang H, Cusin C, Fava M. Is there a placebo problem in antidepressant trials? Curr Top Med Chem 2005;5:1077-1086